Search

Displaying results 1471 - 1480 of 7498 in total
  1. Drug

    Tranexamic acid

    go.drugbank.com/drugs/DB00302
    ApprovedInvestigational

    It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.

  2. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536] … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.

  3. Drug

    Magnesium chloride

    go.drugbank.com/drugs/DB09407
    ApprovedInvestigational

    Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water.

    Mixtures: Dextrose and Electrolyte No. 48, Hemosol Lo
  4. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

  5. Drug

    Benzoin

    go.drugbank.com/drugs/DB14020
    ApprovedWithdrawn

    Benzoin is a white crystalline compound prepared by condensation of benzaldehyde in potassium cyanide, and is used in organic syntheses. … This should not be confused with benzoin gum from STYRAX (see [DB11222]). Benzoin is an FDA-approved colour additive used for marking fruits and vegetables.

  6. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). … Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease.

    Synonyms: N-(n-Butyl)deoxynojirimycin, NB-DNJ
  7. Drug

    Metandienone

    go.drugbank.com/drugs/DB13586
    ApprovedWithdrawn

    It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in sports.

  8. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Moroctocog alfa is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function. … Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia

  9. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    [A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. … at position 1 (N-terminal end).

  10. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency. … Marstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology.